FDA Issues CRL for Cytisinicline NDA, Delaying Approval to H1 2027
ACHV has more than doubled off its 52-week low of $2 on elevated volume (4.4× avg).
Summary
Achieve Life Sciences received a Complete Response Letter (CRL) from the FDA for its Cytisinicline NDA, formally delaying the drug's approval. The CRL cited manufacturing deficiencies at a third-party facility and incomplete product labeling, but importantly, found no issues with clinical efficacy or safety. This follows the company's April 15th disclosure that it anticipated this CRL due to the manufacturing facility's Official Action Indicated (OAI) classification. Achieve plans to resubmit the NDA in Q4 2026 with a new manufacturing partner, targeting potential FDA approval in the first half of 2027. This pushes back the commercial launch timeline and revenue generation for their lead product.
At the time of this announcement, ACHV was trading at $4.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $497.9M. The 52-week trading range was $2.00 to $6.16. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.